NCT00094926View on ClinicalTrials.gov

A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes.

PHASE3CompletedINTERVENTIONAL

Enrollment

275

Participants

Timeline

Start Date

May 31, 2004

Study Completion Date

February 28, 2007

Conditions

Bipolar Disorder

Interventions

DRUG

Risperdal Consta

25, 37.5 or 50mg IM injections every 2wks for 52wks

DRUG

placebo

matching placebo IM injections every 2wks for 52wks

All Listed Sponsors

collaborator

Janssen, LP

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00094926 - A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes. | Biotech Hunter | Biotech Hunter